Epitinib succinate

• CAT Number: I026938
• CAS Number: 2252334-12-4
• Molecular Formula: C28H32N6O6
• Molecular Weight: 548.59
• Purity: ≥95%
• Synonyms: butanedioic acid;4-ethyl-N-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide
• InChI: InChI=1S/C24H26N6O2.C4H6O4/c1-4-17-7-6-8-18(13-17)27-23-19-14-21(22(32-3)15-20(19)25-16-26-23)28-24(31)30-11-9-29(5-2)10-12-30;5-3(6)1-2-4(7)8/h1,6-8,13-16H,5,9-12H2,2-3H3,(H,28,31)(H,25,26,27);1-2H2,(H,5,6)(H,7,8)
• InChIKey: HISXHQFAOANCJX-UHFFFAOYSA-N
• SMILES: CCN1CCN(CC1)C(=O)NC2=C(C=C3C(=C2)C(=NC=N3)NC4=CC=CC(=C4)C#C)OC.C(CC(=O)O)C(=O)O

Epitinib succinate（Cat No.:I026938）is the succinate salt form of epitinib, a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed for treating EGFR-mutant non-small cell lung cancer (NSCLC), particularly with brain metastases. Epitinib is designed to cross the blood-brain barrier efficiently, enabling targeted inhibition of EGFR signaling within the central nervous system. By blocking EGFR autophosphorylation, it suppresses downstream pathways involved in cell proliferation and survival. Epitinib succinate supports research into overcoming resistance in EGFR-driven tumors and improving therapeutic strategies for intracranial malignancies in NSCLC patients.